An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The record Primary purpose is to assess the efficacy of eculizumab in adult patients with
Atypical Hemolytic- Uremic Syndrome (aHUS) to control Thrombotic Microangiopathy (TMA) as
characterized by thrombocytopenia, hemolysis and renal impairment.